[ET Net News Agency, 6 November 2019] Goldman Sachs raised its target price for CSPC
Pharmaceutical (01093) to HK$25.8 from HK$18.9 and maintained its "buy" rating.
CSPC hosted its first open day on 3- October, unveiling details of major R&D programs
and reviewing its commercialization achievements. The research house said this milestone
event: (1) marks CSPC's increasing emphasis on innovative drug R&D in its long-term growth
strategy, with a multi-modality R&D platform that builds on proprietary technologies and
talent recruited globally, (2) reinforces the company's commitment to strong execution and
enhancing corporate governance, (3) enables investors to better assess CSPC's pipeline
value given better visibility and transparency of clinical development progress.
Goldman raised 2020-2021 EPS forecasts by 0.5%/1.5% to factor in the potential launch of
innovative drugs. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
5.860 +0.050 (+0.861%) Others
06/11/2019 16:49
{I-bank focus}Goldman raises CSPC Pharma (01093) to HK$25.8
| Remark: | Real time quote last updated: 18/04/2024 16:47 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |